Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 4
1993 2
1994 5
1995 3
1996 3
1997 4
1998 4
1999 5
2000 8
2001 8
2002 28
2003 34
2004 43
2005 78
2006 105
2007 125
2008 152
2009 176
2010 222
2011 240
2012 334
2013 319
2014 306
2015 266
2016 301
2017 284
2018 279
2019 252
2020 235
2021 235
2022 175
2023 17
Text availability
Article attribute
Article type
Publication date

Search Results

3,732 results
Results by year
Filters applied: . Clear all
Page 1
A Pilot Study of Exenatide Actions in Alzheimer's Disease.
Mullins RJ, Mustapic M, Chia CW, Carlson O, Gulyani S, Tran J, Li Y, Mattson MP, Resnick S, Egan JM, Greig NH, Kapogiannis D. Mullins RJ, et al. Curr Alzheimer Res. 2019;16(8):741-752. doi: 10.2174/1567205016666190913155950. Curr Alzheimer Res. 2019. PMID: 31518224 Free PMC article. Clinical Trial.
BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treating type 2 diabetes, is neuroprotective and disease-modifying in Alzheimer's Disease (AD). ...However, the analysis of secondary outcom …
BACKGROUND: Strong preclinical evidence suggests that exenatide, a glucagon-like peptide-1 (GLP- 1) receptor agonist used for treatin …
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Nauck MA, Quast DR, Wefers J, Meier JJ. Nauck MA, et al. Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14. Mol Metab. 2021. PMID: 33068776 Free PMC article. Review.
BACKGROUND: GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initi …
BACKGROUND: GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been furth …
Exenatide implant therapy in diabetes.
Kalra S, Saboo B. Kalra S, et al. J Pak Med Assoc. 2018 Oct;68(10):1538-1540. J Pak Med Assoc. 2018. PMID: 30317359 Free article. Review.
ITCA 650 is an implantable device which delivers sustained and stable concentrations of the glucagon-like peptide 1 receptor agonist exenatide, when inserted subcutaneously. The article discusses the pharmacodynamics and pharmacokinetics of ITCA 650, and suggests how it' …
ITCA 650 is an implantable device which delivers sustained and stable concentrations of the glucagon-like peptide 1 receptor agonist exen …
Exenatide and weight loss.
Bradley DP, Kulstad R, Schoeller DA. Bradley DP, et al. Nutrition. 2010 Mar;26(3):243-9. doi: 10.1016/j.nut.2009.07.008. Nutrition. 2010. PMID: 20152707 Review.
METHODS: A search through PubMed was performed using exenatide and weight loss as search terms. A second search was performed using exenatide and mechanisms or actions as search terms. RESULTS: In addition to exenatide's action to increase insulin secr …
METHODS: A search through PubMed was performed using exenatide and weight loss as search terms. A second search was performed using …
Exenatide ER-induced eosinophilia.
Eid TJ, Kaur M, Kaur R. Eid TJ, et al. Am J Health Syst Pharm. 2020 Jun 23;77(13):1006-1007. doi: 10.1093/ajhp/zxaa105. Am J Health Syst Pharm. 2020. PMID: 32470112 No abstract available.
Exenatide Attenuates Non-Alcoholic Steatohepatitis by Inhibiting the Pyroptosis Signaling Pathway.
Liu Y, Wang DW, Wang D, Duan BH, Kuang HY. Liu Y, et al. Front Endocrinol (Lausanne). 2021 Apr 19;12:663039. doi: 10.3389/fendo.2021.663039. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 33953700 Free PMC article.
Exenatide (20 g/kg/day, subcutaneous) and specific exenatide inhibitors (20 g/kg/day, intraperitoneal) were used to determine the effects of exenatide on NASH. RESULTS: Exenatide treatment inhibited the pyroptosis signaling pathway to attenuate NASH. . …
Exenatide (20 g/kg/day, subcutaneous) and specific exenatide inhibitors (20 g/kg/day, intraperitoneal) were used to determine …
Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice.
Xu Q, Zhang X, Li T, Shao S. Xu Q, et al. Mol Med. 2022 Dec 3;28(1):144. doi: 10.1186/s10020-022-00574-6. Mol Med. 2022. PMID: 36463128 Free PMC article.
Increased Th17 and decreased Treg cells in peripheral blood were present as diabetes progressed while exenatide corrected this imbalance. Progressive IL-17 + T cell infiltration of pancreatic islets was alleviated by exenatide intervention. ...In addition, PA could …
Increased Th17 and decreased Treg cells in peripheral blood were present as diabetes progressed while exenatide corrected this imbala …
Exenatide-induced granulomatous panniculitis associated with poly(d,l-lactide-co-glycolide).
Zhu CS, Kwan EA, Williams GM, Lewin-Smith M, Lincoln MS, Lee AJ. Zhu CS, et al. J Cutan Pathol. 2022 May;49(5):496-499. doi: 10.1111/cup.14193. Epub 2022 Jan 6. J Cutan Pathol. 2022. PMID: 34954842
Of note, the lesions appeared following exenatide injections in the same locations. Two deep-seated nodules of 1 cm were identified on examination. ...Evaluation of the clinical and histopathologic findings, along with the IR spectroscopy match, determined that exenatid …
Of note, the lesions appeared following exenatide injections in the same locations. Two deep-seated nodules of 1 cm were identified o …
Exenatide improves random-pattern skin flap survival via TFE3 mediated autophagy augment.
Li J, Chen H, Lou J, Bao G, Wu C, Lou Z, Wang X, Ding J, Li Z, Xiao J, Xu H, Gao W, Zhou K. Li J, et al. J Cell Physiol. 2021 May;236(5):3641-3659. doi: 10.1002/jcp.30102. Epub 2020 Oct 12. J Cell Physiol. 2021. PMID: 33044023
Furthermore, we found that exenatide activates the AMPK-SKP2-CARM1 and AMPK-mTOR signaling pathways, which likely lead to exenatide's effects on activating TFE3. Overall, our findings suggest that exenatide may be a potent therapy to prevent flap necro …
Furthermore, we found that exenatide activates the AMPK-SKP2-CARM1 and AMPK-mTOR signaling pathways, which likely lead to exenatid …
Exenatide improves hepatocyte insulin resistance induced by different regional adipose tissue.
Bai C, Wang Y, Niu Z, Guan Y, Huang J, Nian X, Zuo F, Zhao J, Kazumi T, Wu B. Bai C, et al. Front Endocrinol (Lausanne). 2022 Sep 29;13:1012904. doi: 10.3389/fendo.2022.1012904. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36246878 Free PMC article.
Furthermore, these adipokines were significantly inhibited by exenatide. Importantly, the different regional fat depot affects the IRS2/PI3K/Akt2 insulin signaling pathway of hepatocytes. ...In conclusion, exenatide may improve hepatic insulin resistance (IR) by inh …
Furthermore, these adipokines were significantly inhibited by exenatide. Importantly, the different regional fat depot affects the IR …
3,732 results

Searches related to "exenatide"